Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher A Lipinski

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Journal of Chemical Information and Modeling|September 23, 2014
Computational prediction and validation of an expert's evaluation of chemical probesNadia K Litterman, Christopher A Lipinski, Barry A Bunin, et al.
Pharmaceutical Research|August 28, 2015
Thermodynamic Proxies to Compensate for Biases in Drug Discovery MethodsSean Ekins, Nadia K Litterman, Christopher A Lipinski, et al.
Annals of Emergency Medicine|March 23, 2010
Olfactory and gustatory hallucinations presenting as partial status epilepticus because of glioblastoma multiformeDan J Capampangan, Matthew T Hoerth, Joseph F Drazkowski, et al.
Journal of Medicinal Chemistry|December 19, 2009
Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2Nathalie Meurice, Lei Wang, Christopher A Lipinski, et al.
World Journal of Emergency Medicine|September 13, 2014
Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4- methylenedioxypyrovaleroneAaron R Mangold, Thomas P Bravo, Stephen J Traub, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2012
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivoMichael S Saporito, Alexander R Ochman, Christopher A Lipinski, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2012
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetesAlexander R Ochman, Christopher A Lipinski, Jeffrey A Handler, et al.
The Journal of Emergency Medicine|February 1, 2016
Physician in Triage Versus Rotational Patient AssignmentStephen J Traub, Adam C Bartley, Vernon D Smith, et al.
Journal of Medicinal Chemistry|November 22, 2014
Parallel worlds of public and commercial bioactive chemistry dataChristopher A Lipinski, Nadia K Litterman, Christopher Southan, et al.
Journal of Cheminformatics|May 31, 2016
Badapple: promiscuity patterns from noisy evidenceJeremy J Yang, Oleg Ursu, Christopher A Lipinski, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Chemical Information and Modeling|September 23, 2014
Computational prediction and validation of an expert's evaluation of chemical probesNadia K Litterman, Christopher A Lipinski, Barry A Bunin, et al.
Pharmaceutical Research|August 28, 2015
Thermodynamic Proxies to Compensate for Biases in Drug Discovery MethodsSean Ekins, Nadia K Litterman, Christopher A Lipinski, et al.
Annals of Emergency Medicine|March 23, 2010
Olfactory and gustatory hallucinations presenting as partial status epilepticus because of glioblastoma multiformeDan J Capampangan, Matthew T Hoerth, Joseph F Drazkowski, et al.
Journal of Medicinal Chemistry|December 19, 2009
Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2Nathalie Meurice, Lei Wang, Christopher A Lipinski, et al.
World Journal of Emergency Medicine|September 13, 2014
Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4- methylenedioxypyrovaleroneAaron R Mangold, Thomas P Bravo, Stephen J Traub, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 5, 2012
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivoMichael S Saporito, Alexander R Ochman, Christopher A Lipinski, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2012
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetesAlexander R Ochman, Christopher A Lipinski, Jeffrey A Handler, et al.
The Journal of Emergency Medicine|February 1, 2016
Physician in Triage Versus Rotational Patient AssignmentStephen J Traub, Adam C Bartley, Vernon D Smith, et al.
Journal of Medicinal Chemistry|November 22, 2014
Parallel worlds of public and commercial bioactive chemistry dataChristopher A Lipinski, Nadia K Litterman, Christopher Southan, et al.
Journal of Cheminformatics|May 31, 2016
Badapple: promiscuity patterns from noisy evidenceJeremy J Yang, Oleg Ursu, Christopher A Lipinski, et al.
Pageof 4